Arax Advisory Partners
GYRE icon

Arax Advisory Partners’s Gyre Therapeutics GYRE Stock Holding History

Arax Advisory Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$630 Sell
86
-160
-65% -$1.06K ﹤0.01% 5098
2026
Q2 		$1.62K Buy
+246
New +$1.68K ﹤0.01% 4858
2025
Q4 		– Sell
-57
Closed -$426 – 4276
2025
Q3 		$426 Buy
+57
New +$433 ﹤0.01% 3382

Other funds holding GYRE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Arax Advisory Partners's GYRE Position: Q3 2026 in Review

Arax Advisory Partners reduced its Gyre Therapeutics (GYRE) stake by 65% in Q3 2026, selling an estimated $1.06K and leaving 86 shares worth $630. The position accounts for ﹤0.01% of the portfolio, ranked #5098.

Arax Advisory Partners first reported a position in GYRE in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.62K in Q2 2026. 32 funds tracked by Wall St. Rank hold GYRE as of Q3 2026.

  • Arax Advisory Partners held 86 shares of Gyre Therapeutics worth $630 as of Q3 2026.
  • Arax Advisory Partners sold 160 Gyre Therapeutics shares in Q3 2026, an estimated $1.06K.
  • Gyre Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #5098 holding.
  • Arax Advisory Partners first reported a position in Gyre Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Gyre Therapeutics position peaked at $1.62K in Q2 2026.
  • 32 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.